456 related articles for article (PubMed ID: 27840145)
1. Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis.
Xie Y; Feng H; Peng S; Xiao J; Zhang J
Neurosci Lett; 2017 Jan; 636():190-195. PubMed ID: 27840145
[TBL] [Abstract][Full Text] [Related]
2. Plasma homocysteine, folate and vitamin B12 levels in Parkinson's disease in China: A meta-analysis.
Dong B; Wu R
Clin Neurol Neurosurg; 2020 Jan; 188():105587. PubMed ID: 31733593
[TBL] [Abstract][Full Text] [Related]
3. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations.
Ozer F; Meral H; Hanoglu L; Aydemir T; Yilsen M; Cetin S; Ozturk O; Seval H; Koldas M
Neurol Res; 2006 Dec; 28(8):853-8. PubMed ID: 17288745
[TBL] [Abstract][Full Text] [Related]
4. Folic acid with or without vitamin B12 for cognition and dementia.
Malouf M; Grimley EJ; Areosa SA
Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
[TBL] [Abstract][Full Text] [Related]
5. [Homocysteine and cognitive impairment in Parkinson's disease].
Martín-Fernández JJ; Carles-Díes R; Cañizares F; Parra S; Avilés F; Villegas I; Morsi-Hassan O; Fernández-Barreiro A; Herrero MT
Rev Neurol; 2010 Feb 1-15; 50(3):145-51. PubMed ID: 20146187
[TBL] [Abstract][Full Text] [Related]
6. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Anamnart C; Kitjarak R
J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
[TBL] [Abstract][Full Text] [Related]
7. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition.
Triantafyllou NI; Nikolaou C; Boufidou F; Angelopoulos E; Rentzos M; Kararizou E; Evangelopoulos ME; Vassilopoulos D
Parkinsonism Relat Disord; 2008; 14(4):321-5. PubMed ID: 18055246
[TBL] [Abstract][Full Text] [Related]
8. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
[TBL] [Abstract][Full Text] [Related]
9. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Vitamin B Supplementation on Cognition in Elderly Patients With Cognitive-Related Diseases.
Zhang DM; Ye JX; Mu JS; Cui XP
J Geriatr Psychiatry Neurol; 2017 Jan; 30(1):50-59. PubMed ID: 28248558
[TBL] [Abstract][Full Text] [Related]
11. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
Zoccolella S; Lamberti P; Iliceto G; Diroma C; Armenise E; Defazio G; Lamberti SV; Fraddosio A; de Mari M; Livrea P
Clin Chem Lab Med; 2005; 43(10):1107-10. PubMed ID: 16197306
[TBL] [Abstract][Full Text] [Related]
12. Plasma Homocysteine and Serum Folate and Vitamin B
Ma F; Wu T; Zhao J; Ji L; Song A; Zhang M; Huang G
Nutrients; 2017 Jul; 9(7):. PubMed ID: 28698453
[TBL] [Abstract][Full Text] [Related]
13. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.
Rogers JD; Sanchez-Saffon A; Frol AB; Diaz-Arrastia R
Arch Neurol; 2003 Jan; 60(1):59-64. PubMed ID: 12533089
[TBL] [Abstract][Full Text] [Related]
14. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine in restless legs syndrome.
Bachmann CG; Guth N; Helmschmied K; Armstrong VW; Paulus W; Happe S
Sleep Med; 2008 May; 9(4):388-92. PubMed ID: 17900981
[TBL] [Abstract][Full Text] [Related]
16. Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease.
Christine CW; Auinger P; Joslin A; Yelpaala Y; Green R;
Mov Disord; 2018 May; 33(5):762-770. PubMed ID: 29508904
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Camicioli RM; Bouchard TP; Somerville MJ
Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
[TBL] [Abstract][Full Text] [Related]
18. Association of cognitive impairment with plasma levels of folate, vitamin B12 and homocysteine in the elderly.
Dimopoulos N; Piperi C; Salonicioti A; Psarra V; Gazi F; Nounopoulos C; Lea RW; Kalofoutis A
In Vivo; 2006; 20(6B):895-9. PubMed ID: 17203786
[TBL] [Abstract][Full Text] [Related]
19. Effects of differences in serum total homocysteine, folate, and vitamin B12 on cognitive impairment in stroke patients.
Jiang B; Chen Y; Yao G; Yao C; Zhao H; Jia X; Zhang Y; Ge J; Qiu E; Ding C
BMC Neurol; 2014 Nov; 14():217. PubMed ID: 25433800
[TBL] [Abstract][Full Text] [Related]
20. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P
Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
